



Medical Coverage Policy

Effective Date05/15/2025

Next Review Date04/15/2026

Coverage Policy Number..... 0480

Balloon Sinus Ostial Dilation for Chronic Sinusitis and Eustachian Tube Dilation

Table of Contents

Overview	2
Coverage Policy	2
Health Equity Considerations.....	3
General Background.....	3
Medicare Coverage Determinations	19
Coding Information	19
References.....	20
Revision Details.....	27

Related Coverage Resources

[Drug-Eluting Devices for Use Following Endoscopic Sinus Surgery Rhinoplasty, Vestibular Stenosis Repair and Septoplasty](#)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers

must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This Coverage Policy addresses balloon sinus ostial dilation, also called balloon sinuplasty, for the treatment of chronic sinusitis and other indications, including recurrent acute rhinosinusitis. The Policy also addresses Eustachian tube dilation for all indications including Eustachian tube dysfunction.

Coverage Policy

Balloon Sinus Ostial Dilation

Balloon sinus ostial dilation (balloon sinuplasty) is considered medically necessary in each of the sinuses being considered for dilation (i.e., maxillary, frontal or sphenoid) for treatment of EITHER of the following conditions:

- Chronic rhinosinusitis when ALL of the following criteria are met:
 - presence of two or more of the following signs/symptoms for more than three consecutive months:
 - nasal obstruction
 - anterior or posterior mucopurulent (foul) drainage
 - facial pain, pressure and/or fullness over the affected sinus
 - decreased sense of smell
 - evidence of chronic rhinosinusitis on computerized tomography (CT) scan in each of the sinuses being considered for treatment including ANY of the following:
 - mucosal thickening
 - air fluid levels
 - opacification
 - nasal polyposis
 - failure, intolerance or contraindication of medical management when ALL the following have been tried, during at least eight (8) consecutive weeks:
 - antibiotic therapy
 - steroid spray
 - antihistamine nasal spray and/or decongestant
 - nasal saline irrigation
- Recurrent acute rhinosinusitis when ALL of the following criteria are met:
 - Four or more episodes per year of acute rhinosinusitis
 - Nasal endoscopy findings suggestive of significant disease (i.e., abnormal mucosal status, fluid, or infection)
 - CT scan evidence of ostial occlusion and mucosal thickening in each paranasal sinus being considered for treatment.
 - Sinonasal symptoms (e.g., pain, pressure, drainage, reduced sense of smell)

Balloon sinus ostial dilation (balloon sinuplasty) is considered not medically necessary for all other indications.

Balloon sinus ostial dilation (balloon sinuplasty) when used as an adjunctive procedure during functional endoscopic sinus surgery (FESS) in the same sinus cavity is considered to be an integral part of the primary procedure and not separately reimbursable.

Eustachian Tube Dilation

Unilateral or bilateral Eustachian tube balloon dilation (ETBD) is considered medically necessary once per lifetime for the treatment of chronic obstructive Eustachian tube dysfunction when ALL of the following criteria are met:

- age 18 years or older
- any of the following symptoms continuously for at least six months:
 - aural fullness
 - aural pressure
 - hearing loss
 - autophony
- history of chronic ear disease or intolerance to barometric changes greater than six months
- prior evaluation with nasal endoscopy
- BOTH of the following prior to ETBD:
 - two abnormal tympanograms (Type B or C)
 - two abnormal tympanic membrane examinations (i.e., retracted membrane, effusion, perforation)
- failure, intolerance or contraindication to appropriate medical management including at least four weeks of a nasal topical spray
- if patient has a history of tympanostomy tube placement, symptoms of Eustachian tube obstruction improved while tubes were patent

Eustachian tube balloon dilation (ETBD) is considered not medically necessary for all other indications.

Health Equity Considerations

Health equity is the highest level of health for all people; health inequity is the avoidable difference in health status or distribution of health resources due to the social conditions in which people are born, grow, live, work, and age.

Social determinants of health are the conditions in the environment that affect a wide range of health, functioning, and quality of life outcomes and risks. Examples include safe housing, transportation, and neighborhoods; racism, discrimination and violence; education, job opportunities and income; access to nutritious foods and physical activity opportunities; access to clean air and water; and language and literacy skills.

General Background

Balloon Sinus Ostial Dilation

Rhinosinusitis, also referred to as sinusitis, is an inflammation of the mucous membrane of the paranasal sinuses and nasal cavity. It affects all age groups and can be caused by infection,

airborne allergens (e.g., dust mites, mold, pollen) or autoimmune deficiencies. There are three classifications of rhinosinusitis. Acute rhinosinusitis (ARS) typically lasts four weeks or less. Subacute sinusitis lasts 4–12 weeks, and chronic rhinosinusitis (CRS) lasts for more than 12 weeks, with or without exacerbation, and can continue for months or years. CRS leads to thickening of the paranasal sinuses due to constant inflammation. The condition can occur with or without nasal polyps. Recurrent acute rhinosinusitis (RARS) is diagnosed when four or more episodes of acute rhinosinusitis occur in the past 12 months without signs or symptoms of rhinosinusitis between episodes. The four cardinal signs/symptoms of CRS and RARS are: nasal obstruction; facial congestion, pressure, and or fullness; anterior and/or posterior mucopurulent drainage; and hyposmia (decreased ability to smell). CRS and RARS are associated with sinus edema and impaired mucociliary clearance (American Academy of Otolaryngology-Head and Neck Surgery [AAO-HNS], 2015; Parikh, et al., 2014; Ahmed, et al., 2011; Hopkins, et al., 2007).

The diagnosis of CRS and RARS is based on presenting signs and symptoms, clinical examination using anterior rhinoscopy, or nasal endoscopy. Radiological evidence is plain films, computed tomography (CT) scan, and in some cases, MRI is a part of the work-up for these patients. CT scan is the standard radiologic examination obtained when endoscopic sinus surgery is being considered. Radiological characteristics of sinusitis include air fluid levels, mucosal thickening greater than three millimeters, nasal polyposis, opacification, bony remodeling and thickening. CT is also used to determine the Lund-Mackey Score for assessing the severity of rhinosinusitis. This scale grades the right and left sides independently, looking at the maxillary, anterior ethmoids, posterior ethmoids, sphenoid, and frontal sinuses, as well as the ostiomeatal complex. Each sinus is scored a 0 (no abnormality), 1 (partial opacification), or 2 (total opacification), and the ostiomeatal complex is scored either a 0 or 2 (for presence or absence of disease). Each side is divided into six regions, corresponding to the location of specific sinuses. Ethmoid sinuses are divided into two regions, anterior and posterior, and the ostiomeatal complex is evaluated separately. Each sinus is scored as 0, 1, or 2 based on the severity of mucosal inflammation or fluid accumulation. Thus the score can range from 0, complete lucency of all 12 regions, to 24, complete opacity of all regions. Studies have reported an increased complication rate following surgery with increasing Lund-Mackay scores (Brook, 2018; Vartanian, 2016; Ramanan, 2016; Brook, 2015; American Academy of Otolaryngology -Head and Neck Surgery [AAO-HNS], 2015; Parikh, et al., 2014; Noorian and Motaghi, 2012; Rege et al., 2012; Ahmed, et al., 2011; Huang, et al., 2009; Hopkins, et al., 2007).

Because CRS is typically not cured, medical management is focused on minimizing mucosal inflammation and edema to prevent obstruction and minimize the incidence of infections and acute exacerbations. Medical treatment is typically tried for at least eight weeks and includes nasal saline irrigation, topical and systemic glucocorticoids, two or more antibiotics, and/or antileukotriene agents. When the patient becomes unresponsive to medical management, surgical intervention to clean and drain the sinuses may be indicated. In cases where obstruction of the nasal passages is present (e.g., polyps, deviated septum), surgery to correct the obstruction may be done (Brook, 2016; Brook, 2015; American Academy of Otolaryngology -Head and Neck Surgery [AAO-HNS], 2015; Parikh, et al., 2014).

Functional endoscopic sinus surgery (FESS), also referred to as endoscopic sinus surgery (ESS), is the standard surgical procedure for CRS that is unresponsive to medical management. The goal of surgery is to improve sinus ventilation and drainage by enlarging the openings of the sinuses, removing any polyps and correcting significant structural problems that may be hindering drainage. FESS involves the insertion of an endoscopy into the nose for direct visual exam of the openings into the sinuses. Special instruments are used along with the endoscope to remove the blockages and improve breathing. Complications that can occur during ESS include: scarring and adhesions, intraoperative bleeding that can obscure surgical visualization, orbital injury, and accidental penetration of the brain (AAO-HNS, 2015; Parikh, et al., 2014; Brown, et al., 2006).

Balloon sinus ostial dilation, also known as balloon sinuplasty and balloon catheter sinusotomy, has become an accepted alternative procedure to functional endoscopic sinus surgery (FESS) for the treatment of CRS and RARS in a select subset of patients. Like FESS, balloon sinuplasty is intended to allow access to and ventilation of obstructed sinuses. The procedure is less invasive than FESS and proposed to have minimal bleeding, scarring and less postoperative pain. Risks of balloon sinuplasty include tissue and mucosal trauma, infection or possible optic injury. Basic equipment includes a sinus guidewire, a sinus delivery catheter, a sinus balloon and an inflation device. Guided by X-ray images or by a lighted fiberoptic tip, the catheter is threaded up to the opening of the blocked or poorly draining sinus and the guidewire is passed through the opening of the sinus. The guidewire is passed from the nasal cavity into the specific sinus being addressed and a balloon dilating catheter is passed over the wire to the narrowest part of the sinus drainage pathway. The balloon is then briefly inflated to a high pressure (up to 12 atmospheres). The pressure from the balloon widens the outflow tract of the sinus by fracturing bone and moving it outward along the mucous membrane without tissue removal. The balloon is then deflated and the catheter is removed (Hayes, 2017, reviewed 2018; Hepworth, 2016; Ahmed, et al., 2011).

When performed alone, balloon sinuplasty is an accepted procedure for a select subset of adult patients, age 18 years and older, with chronic rhinosinusitis (CRS) or recurrent acute rhinosinusitis (RARS). Appropriate CRS surgical candidates have failed at least eight weeks of consecutive medical therapy including at least two antibiotics, steroid nasal spray, antihistamine nasal spray and/or decongestant and nasal saline washes. Computerized tomography (CT) scan should show air fluid levels, opacification or nasal polyps. RARS surgical candidates have had four or more episodes of acute rhinosinusitis per year with relief of symptoms between episodes. Nasal endoscopy results should include abnormal mucosal status, fluid or infection. Additionally, a CT scan should show ostial occlusion and mucosal thickening of the paranasal sinuses. When balloon sinuplasty is used as an adjunctive procedure with FESS it is considered an integral part of the procedure.

Balloon sinuplasty has been proposed for the treatment of other conditions including headaches unrelated to CRS, nasal obstruction and obstructive sleep apnea (AAO-HNS, 2018). There is insufficient evidence in the peer-reviewed literature to support balloon sinuplasty for these other indications.

U.S. Food and Drug Administration (FDA):

Balloon Sinuplasty devices are approved by the FDA 510(k) process as Class I devices. One of the first balloon inflation devices approved was the Relieva Sinus Balloon Inflation Device (Acclarent, Inc., Menlo Park, CA) in 2005. The 2008 approved devices, Relieva Sinus Balloon Catheter and the Relieva Acella Sinus Balloon Catheter, are also Class I devices. These devices are approved to "dilate sinus ostia and spaces within the paranasal sinus cavities for diagnostic and therapeutic procedures." The balloon may be inflated to dilate the frontal recess, frontal sinus ostia and spaces within the frontal sinus cavity. "For children aged 17 and under, the balloon catheter system is intended to dilate sinus ostia and spaces associated with the maxillary sinus for diagnostic and therapeutic procedures". The DSS Balloon Catheter (Intuit Medical Products, LLC., Sugar Hill, GA) is also FDA approved for children aged 17 years and under.

The Dillard Nasal Balloon Catheter (Intuit Medical Products, LLC) was FDA 510(k) approved as a Class I device on January 3, 2020 (K181546). The Dillard Nasal Balloon (DNB) Catheter is "intended to provide increased intranasal space to facilitate access for endonasal and transnasal procedures and/or temporarily address nasal obstruction by displacing the inferior turbinate and lower nasal septum" (FDA 2020).

The Sinusway Dilation System (3NT Medical Ltd., Kfar Saba, Israel) "is intended to access and treat the frontal, maxillary and sphenoid sinuses in sinus procedures in adults using a trans-nasal approach, by dilation and displacement of the anatomic structures along the sinus drainage pathways". The System was FDA 510(k) approved as a Class I device in 2018 (K181838).

The Acclarent Airway Balloon Catheter is a catheter with a high pressure balloon on the distal tip. The device is designed with a coaxial lumen for inflation and guidewire access, if required. There are two accessories for the Airway Balloon Catheter: the Inflation Device and the Relieva Vigor Guidewire. The Acclarent Relieva SpinPlus Balloon Sinuplasty System was approved in 2015 to "provide a means to access the sinus space and illuminate within and transilluminate across nasal and sinus structures; dilate the sinus ostia and spaces associated with the paranasal sinus cavities for diagnostic and therapeutic procedures; and irrigate from within a target sinus for therapeutic procedures and to facilitate diagnostic procedures". The FDA issued a Class I device 510(k) approval for the RELIEVA ULTIRRA on Mar 1, 2019. This device is intended to provide the same diagnostic and therapeutic benefits as the previous Acclarent Airway Balloon Catheter. These approved indications also include children aged 17 years and under. As a Class I, the device falls into a generic category and FDA clearance is not required before marketing the device in the US. The manufacturer is required to register their establishment with the FDA.

The XprESS Multi-Sinus Dilation System (Entellus Medical, Inc., Plymouth, MN) is a Class I device intended to "access and treat the maxillary ostia/ethmoid infundibula in patients 2 years and older, and frontal ostia/recesses and sphenoid sinus ostia in patients 12 years and older using a trans-nasal approach. The bony sinus outflow tracts are remodeled by balloon displacement of adjacent bone and paranasal sinus structures." The Dillard Sinuplasty Balloon Catheter (Intuit Medical Products, LLC, Sugar Hill, GA) (DSS Balloon Catheter) is intended "to dilate sinus ostia and spaces within the paranasal sinus cavities for diagnostic and therapeutic procedures. For children aged 17 years and under, the balloon catheter system is intended to dilate sinus ostia and spaces associated with the maxillary sinus for diagnostic and therapeutic procedures". The Sinus Dilation System with Cannulated Instrument, a modification to ENTrigue Sinus Dilation System, was FDA approved in 2013 for use in surgical procedures to access, examine or treat the nasal and paranasal tissues (K163509).

The Nuvent EM Sinus Dilation System (Medtronic Xomed, Inc., Jacksonville FL) is intended for use in conjunction with the Medtronic Computer-Assisted Surgery System during sinus procedures when surgical navigation or image-guided surgery may be necessary (FDA 510(k) K152121). This system combines electromagnetic (EM) "plug and play" tracking capability with the pathway expansion effects of balloon dilation technology and an inflator. Each of the three types of sinus seekers (frontal, maxillary and sphenoid) has a unique shape and angle that allows for entry into the sinus outflow tract. The inflator consists of a plunger, barrel and extension tube (FDA, 2013).

In contrast to the high pressure inflation systems, the Vent-Os Sinus Dilation System (SinuSys Corp., Palo Alto, CA), uses low-pressure, self-expanding technology and is proposed to open the maxillary ostia gently and gradually. The device was FDA approved in 2013 to dilate the maxillary sinus in adults for therapeutic and diagnostic procedures (K133016). The procedure is performed in the office (FDA, 2013; SinuSys Corp, 2016).

Literature Review – Chronic Rhinosinusitis

Randomized controlled trials have compared FESS to balloon sinuplasty of the frontal, maxillary or sphenoid sinuses for the treatment of CRS. The studies have small patient populations and short-term follow-up. However, outcomes have shown that balloon sinuplasty is noninferior to FESS with shorter operative times, less bleeding and few to no reported complications (Chandra, et al., 2016; Bikhazi, et al., 2014; Marzetti, et al., 2014; Achar, et al., 2012; Plaza, et al., 2011). Balloon sinuplasty has evolved into an accepted alternative procedure for CRS.

Numerous case series have also been conducted to evaluate the safety and efficacy of balloon sinuplasty. Subjects were aged 18 years and older with CRS for more than 12 weeks that was unresponsive to medical management (e.g., antibiotic therapy, inhaled and/or systemic corticosteroids, decongestants, saline irrigations). Reported post-operative outcomes included: functional patency in 80.5%–97% of patients; statistically significant improvement in sino-nasal outcome (SNOT-20) scores; and CT Lund-Mackey scores and revision rates 3%–7.4%. The studies are limited by the small patient populations (n=37–115) and short-term follow-ups (e.g., 2–12 months) (Sikand, et al., 2015; Gould, et al., 2014; Levine, et al., 2013; Albritton, et al., 2012; Weiss, et al., 2008; Kuhn, et al., 2008). Published studies evaluating the outcomes of balloon sinuplasty in children are lacking (Ramadan, et al., 2010).

Brodner et al. (2013) conducted a prospective case series to evaluate the safety and efficacy of balloon sinuplasty dilation (BSD) (XprESS) in 175 patients and 497 sinuses (279 frontal, 138 sphenoid, 80 maxillary). Patients were 18 years and older, scheduled for FESS prior to the study, and had a CT scan within 12 months of the surgery. At the one-year follow-up, 44 patients reported significant improvement in sinus symptoms ($p < 0.0001$). At the one-year follow-up, ostial patency was maintained in 91.6% of sinuses and one revision surgery was required.

Karanfilov et al. (2012) conducted a prospective, multicenter, case series to evaluate the safety and efficacy of balloon sinuplasty dilation (BSD) in 203 subjects (552 sinuses). Patients aged 18 years and over with CRS had failed the minimum maximal treatment protocol (i.e., more than 3–6 weeks of broad-spectrum or culture-directed antibiotics, intranasal steroid spray and/or oral steroids if polyps or severe inflammation were present; antihistamines and/or decongestants clinically indicated; and routine use of nasal saline irrigation during treatment course). CRS diagnosis was made according to the AAO-HNS CRS definition which includes ≥ 12 weeks of two or more major signs/symptoms and inflammation by purulent mucus/edema, presence of polyps, or radiographic imaging. The technical dilation success was 93.3% for maxillary sinuses, 90.5% for sphenoid and 93.7% for frontal. There was significant improvement in the Sino-Nasal Outcome Test (SNOT-20) and the Lund-Mackay CT scores ($p < 0.0001$, each). Patients (82.3%) considered the procedure tolerable or highly tolerable.

Literature Review – Recurrent Acute Rhinosinusitis

Sikand et al (2019) conducted a randomized, controlled trial comparing in-office balloon sinus dilation versus medical management for adults diagnosed with recurrent acute rhinosinusitis (RARS). Twenty-nine patients underwent balloon sinus dilation with medical management while 30 patients received medical management alone. Outcomes were measured at 24 weeks, and the patients were followed up to 48 weeks. Results included the patient-reported quality of life (QOL), as measured by the Chronic Sinusitis Survey (CSS) total score from baseline to 24 weeks, was significantly greater in the balloon sinus dilation plus medical management group compared with the medical management-only group (37.3 ± 24.4 [$n = 26$] vs 21.8 ± 29.0 [$n = 27$]; $p = 0.0424$).

Gould et al. (2014) conducted a prospective, multicenter study performing balloon dilation of the maxillary sinuses/ethmoid infundibula with or without frontal or sphenoid ostial dilation in the physician's office under local anesthesia for adults diagnosed with CRS or RARS. Three hundred seven sinuses among 81 subjects successfully completed ostial dilations. Clinically and statistically significant ($p < 0.0001$) mean SNOT-20 symptom improvement was observed at one and six months and sustained through one year. The Rhinosinusitis Symptom Inventory (RSI) treatment effect for all major rhinosinusitis symptoms was "large" and improvement in each was significant ($p < 0.0001$). Compared with the previous one year period, patients reported an average of 2.3 fewer acute sinus infections ($p < 0.0001$), 2.4 fewer antibiotic courses taken ($p < 0.0001$), and 3.0 fewer sinus-related physician visits ($p < 0.0001$) after balloon dilation.

Levine et al. (2013) conducted a prospective, multi-institutional study that performed in-office balloon dilation of maxillary sinus ostia and ethmoid infundibula to treat both chronic rhinosinusitis (CRS) and recurrent acute rhinosinusitis (RARS). Seventy-four patients, all confirmed by computed tomography to have disease in the maxillary and anterior ethmoid sinuses, were followed for one year. The mean improvement on the SNOT-20 at one year was clinically and statistically significant ($p < 0.0001$), with no significant difference between the CRS and RARS patient outcomes. The treatment effect was the same in the CRS and RARS subgroups and was either “moderate” or “large” for ten of twelve symptoms. The mean numbers of antibiotic courses ($p \leq 0.001$), sinus-related physician visits ($p < 0.0001$) and number of acute sinus infections ($p < 0.001$) decreased significantly in both subgroups.

Professional Societies/Organizations

American Academy of Allergy, Asthma and Immunology (AAAAI): A joint task force published a practice parameter on the medical management of chronic rhinosinusitis with nasal polyposis (CRSwNP). They defined CRSwNP as an inflammatory disease of the nasal mucosa lasting at least twelve weeks. In people with CRSwNP, the guideline panel suggested intranasal corticosteroid (INCS) rather than no INCS (conditional recommendation). The small-to-moderate treatment effect and low certainty of evidence when all of the different INCS delivery methods were considered together for the two critical outcomes (disease-specific quality of life and nasal obstruction symptoms), balanced by the low burdens of medications, drove the conditional recommendation. The guideline indicated delivery method of the INCS as potentially important with stent, spray and EDS being the most beneficial. Clinical outcomes for sprays were found to improve symptoms, sense of smell and potentially reduce the need for rescue surgery. Adverse effects were no different than those observed with placebo. While there was moderate certainty of evidence for safety of INCS spray, there was low or very low certainty of evidence for the other delivery systems. The group concluded that more, larger, direct comparison RCTs of INCS treatments and comparison with other management options will lead to more definitive results. (Rank et al., 2022).

American Academy of Allergy, Asthma and Immunology (AAAAI): In the practice parameter on rhinosinusitis, AAAAI defines CRS as persistent symptoms of rhinosinusitis for 12 weeks or longer. Signs and symptoms include purulent rhinorrhea, postnasal drainage, anosmia, nasal congestion, facial pain or pressure, or headache and are associated with objective evidence of inflammation observed on nasal endoscopy and/or CT scan. CRS may occur with or without polyps. Sinus CT scan is the preferred imaging modality and the gold standard to clarify the extent of disease and specific location or locations of obstruction in acute or chronic sinus disease. CT scan is required before surgical intervention or if rhinosinusitis complications are suspected (Dass and Peters, 2016).

American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS): The AAO-HNS (2018) developed a clinical consensus statement on balloon dilation of the paranasal sinuses. The target population included adults \geq age 18 years with chronic or recurrent rhinosinusitis (with or without nasal polyps, with or without prior sinus surgery) for whom sinus ostial dilation (SOD) was recommended. SOD was defined as endoscopic use of a balloon device to enlarge or open the outflow tracts of the maxillary, frontal, or sphenoid sinuses, as a standalone procedure or with endoscopic surgery. The use of serial dilations over time in the same patient was not considered. According to AAO-HNS, there has been an increasing rate of utilization of SOD without a reduction in the number of traditional functional endoscopic sinus surgeries being performed. Due to limited evidence to support a guideline, the topic of SOD was selected for clinical consensus statement (CCS) development. Based on a systematic review of the literature and expert consensus, the Society’s statements included the following:

- Balloon dilation is not appropriate for patients who are without both sinonasal symptoms and positive findings on CT.
- Balloon dilation is not appropriate for the management of headache in patients who do not otherwise meet the criteria for chronic sinusitis or recurrent acute sinusitis.
- Balloon dilation is not appropriate for the management of sleep apnea in patients who do not otherwise meet the criteria for chronic sinusitis or recurrent acute sinusitis.
- CT scanning of the sinuses is a requirement before balloon dilation can be performed.
- Balloon dilation is not appropriate for patients with sinonasal symptoms and a CT that does not show evidence of sinonasal disease.
- Balloon dilation can be appropriate as an adjunct procedure to FESS in patients with chronic sinusitis without nasal polyps.
- There can be a role for balloon dilation in patients with persistent sinus disease who have had previous sinus surgery.
- There is a role for balloon sinus dilation in managing patients with recurrent acute sinusitis as defined in the AAO-HNSF guideline based on symptoms and the CT evidence of ostial occlusion and mucosal thickening.
- Balloon dilation can improve short-term quality-of-life outcomes in patients with limited CRS without polyposis.
- Balloon dilation can be effective in frontal sinusitis.

In a 2017 position statement on dilation of the sinuses, AAO-HNS stated that sinus ostial dilation (e.g., balloon ostial dilation) is an appropriate therapeutic option for selected patients with chronic rhinosinusitis (CRS) and acute rhinosinusitis (RARS) who have failed medical therapy. Clinical diagnosis of CRS and RARS should be based on symptoms of sinusitis and supported by nasal endoscopy documenting sinonasal abnormality or mucosal thickening on computed tomography of the paranasal sinuses. The Society noted that sinus ostial dilation can be used alone or in conjunction with other instruments. The final decision regarding use of techniques or instrumentation for sinus surgery is the responsibility of the attending surgeon.

The AAO-HNS (2015) clinical practice guideline on adult sinusitis defines chronic rhinosinusitis as twelve weeks or longer of two or more of the following signs and symptoms:

- mucopurulent drainage (anterior, posterior, or both),
- nasal obstruction (congestion),
- facial pain/pressure/fullness, or
- decreased sense of smell

AND inflammation as documented by one or more of the following:

- purulent (not clear) mucus or edema in the middle meatus or anterior ethmoid region,
- polyps in nasal cavity or the middle meatus, and/or
- radiographic imaging showing inflammation of the paranasal sinuses

The Society recommends that the clinician confirm the diagnosis of CRS with objective documentation of sinonasal inflammation using anterior rhinoscopy, nasal endoscopy, or computed tomography. The diagnosis CRS cannot be made based on signs and symptoms alone. CT of the paranasal sinuses should be obtained when endoscopic sinus surgery is considered or planned for patients with CRS.

American Rhinologic Society (ARS): In January 2023, the ARS issued a position statement in support of the use of sinus ostial dilation (e.g., balloon ostial dilation) as a therapeutic option for selected patients with chronic rhinosinusitis (CRS) and recurrent acute rhinosinusitis (RARS) who have failed appropriate medical therapy. Support of this treatment strategy is based on clinical consensus statements and primary research evidence. Clinical diagnosis of CRS and RARS should be based on symptoms of sinusitis and supported by objective evidence (nasal endoscopy

documenting sinonasal abnormality or mucosal thickening on CT scan of the paranasal sinuses) prior to considering the use of balloon sinus dilation. They concluded this approach may be used alone or in conjunction with traditional endoscopic sinus surgery.

Eustachian Tube Balloon Dilation

Eustachian tube dysfunction (ETD), or eustachian tube dilatatory dysfunction (ETDD), occurs in about 1% of the adult population. There is a lack of consensus on the definition of ETD. ETD ranges from obstructive dysfunction, in which there is failure of the Eustachian tube (ET) to open and provide adequate ventilation to the middle ear, to patulous ETD in which there is failure of the ET to close. Patients may move back and forth on this spectrum, creating difficulties in diagnosis and appropriate treatment. Clinical signs include: sensations of pressure; full or heavy ear; fluctuating hearing loss; popping/snapping/buzzing sounds; and in severe cases vertigo. Untreated ETD may lead to hearing loss, chronic otitis media or cholesteatoma. Endoscopic assessment of the pharyngeal opening of the tube mainly provides anatomic information, and functional correlations are not well established for obstructive Eustachian tube dysfunction. The choice of management strategies for isolated Eustachian tube dysfunction remains controversial due to the lack of evidence. The treatment of ETD should be directed at the underlying etiology, if known. The usual treatments for obstructive Eustachian tube dysfunction include decongestants, oral and nasal steroids, antihistamines, pressure equalization methods, nasal douching, and antibiotics. Treatment primarily treats the symptoms and not the underlying cause of ETD (Poe, et al., 2018; Poe and Hanna, 2018; Schmitt, et al., 2018; Hayes, 2017; Tisch, et al., 2017).

Balloon dilation of the Eustachian tube, or balloon Eustachian tuboplasty (BET) is a novel, minimally invasive method proposed for the treatment of chronic obstructive Eustachian tube dysfunction. A Eustachian tube balloon dilation system is a device that includes a flexible catheter attached to an inflatable balloon. The system is intended for use in dilating the cartilaginous portion of the Eustachian tube to improve ET function (Luukkainen, et al., 2018; Poe, et al., 2018; Poe and Hanna, 2018; Schmitt, et al., 2017; Tisch, et al., 2017).

Endoscopic balloon dilation of the Eustachian tube ("tuboplasty") is a minimally invasive procedure for treating chronic, obstructive Eustachian tube dysfunction in adults. Small observational studies indicate that it is also safe and moderately successful in improving OME in children. Failure of balloon dilation may be related to thickened mucosa or adenoid tissue obstruction at the Eustachian tube orifice that acts as a barrier to middle ear ventilation and is unresponsive to balloon dilation. Although balloon dilation of the Eustachian tube appears to be promising and experience in children is increasing, additional studies are necessary to determine which children with OME are most likely to benefit (Marom et al., 2024). Future prospective trials to confirm safety and efficacy are warranted (Merrill et al. 2023).

Unilateral or bilateral Eustachian tube balloon dilation (ETBD) is a treatment option for a patient who is age 18 years or older and has a diagnosis of chronic obstructive ETD. Patients with obstructive ETD experience aural fullness (clogged ear sensation), aural pressure, otalgia (earache), hearing loss or autophony continuously, rather than episodic, for greater than three months. Evaluation for ETD may include clinical history, physical exam, tympanometry, audiometry, otoscopy, otomicroscopy, nasal endoscopy or nasopharyngoscopy. Potential candidates for ETBD should have either a Type B (a flat or unidentifiable peak suggesting middle ear effusion) or Type C (a negative pressure or peak below 100 max pressure [daPa] suggesting ETD) tympanogram result on tympanometry, or have an abnormal tympanic membrane found on exam. ETD and any co-occurring conditions such as allergic rhinitis, rhinosinusitis, middle ear effusion and Laryngopharyngeal reflux are typically treated prior to undergoing ETBD. Medical management may include systemic decongestants, antihistamines, nasal topical decongestants, or

corticosteroid sprays. Tympanostomy tubes create a route for ventilation of the middle ear to help alleviate obstructive ETD symptoms but does not address the root problem and could result in infection, otorrhea, persistent perforation, and tympanosclerosis. If the patient has a history of tympanostomy tube placement, symptoms of ETD should have improved while the tubes were patent (Hayes, 2021; Tucci, et al., 2019).

ETBD has been proposed for the treatment of other conditions including: craniofacial syndromes; neoplasms causing obstruction of the Eustachian tube; systemic mucosal or autoimmune inflammatory disease affecting the mucosa of the nasopharynx and patulous Eustachian tube dysfunction (Hayes, 2021; Tucci, et al., 2019). There is insufficient evidence in the published peer-reviewed literature to support ETBD for these other conditions.

US Food and Drug Administration (FDA): Balloon sinuplasty and tuboplasty devices are approved by the FDA 510(k) Premarket Approval process as Class I-II devices under the product code LRC. This is a broad product code category that includes a variety of devices used in ear, nose, and throat surgeries. There are a multitude of FDA approved balloon sinuplasty/tuboplasty devices on the market.

The Acclarent Aera Eustachian Tube Balloon Dilation System (Acclarent, Inc., Irvine CA) is FDA approved as a De Novo Class II device. The Food and Drug Administration Modernization Act of 1997 (FDAMA) added the De Novo classification option, also known as Evaluation of Automatic Class III Designation, to provide an alternate pathway to classify novel devices of low to moderate risk that are not substantially equivalent to an existing FDA approved device (predicate device). Devices that are classified through the De Novo process may be marketed and used as predicates for future 510(k) submissions and are typically Class II devices. The Acclarent System is FDA approved to “dilate the Eustachian tube for treatment of persistent Eustachian tube dysfunction in adults ages 22 years and older. January 2018 the Acclarent System was FDA approved (K171761) as a 510(k) Class II device intended to “dilate the Eustachian tube for treatment of persistent Eustachian tube dysfunction in patients ages 18 and older” (FDA, 2018). In December 2023, the Acclarent Aera Eustachian Tube Balloon Dilation System was FDA approved (K230742) for an expanded indication for patients ages 8-17 years, alone or in combination with adjunctive procedures, to treat patients with objective signs of persistent obstructive Eustachian tube dysfunction from inflammatory pathology, resulting in chronic otitis media with effusion refractory to at least one surgical intervention for persistent obstructive Eustachian tube dysfunction.

The Acclarent System includes the Eustachian Tube Balloon Catheter (ETBC) and the Eustachian Tube Guide Catheter (ETGC). The system also includes the Acclarent SE Inflation Device (or Acclarent Balloon Inflation Device) and Relieva Extension Tubing. The Acclarent SE Inflation Device (or Acclarent Balloon Inflation Device) is used to inflate the ETBC. The Acclarent SE Inflation Device and Acclarent Balloon Inflation Device are FDA cleared devices (K150172 and K052198, respectively). The Relieva Extension Tubing may be used to connect the Balloon Catheters and the Inflation Device when additional tubing length is required. The Relieva Extension Tubing is a Class I exempt device (FDA, 2016). In addition, the Acclarent SE Inflation Device and the Relieva Sinus Balloon Inflation Device are used to inflate the ETBC (Hayes, 2017).

In August 2023, the TubaVent Balloon Dilatation System (Spiggle & Theis Medizintechnik, Germany) received FDA 510(k) premarket notification clearance (K223542) for the indicated use of dilating the cartilaginous portion of the Eustachian tube for treatment of persistent obstructive Eustachian tube dysfunction in patients 18 years and older.

In April 2023, FDA 510(k) status was granted under K230065 for the VenSure Balloon Dilation System. The VenSure Balloon Dilation System is used to access and treat the frontal ostia/recesses, sphenoid sinus ostia and maxillary ostia/ethmoid infundibula in adults using a

trans-nasal approach. The bony sinus outflow tracts are remodeled by balloon displacement of adjacent bone and paranasal sinus structures. To dilate the cartilaginous portion of the Eustachian tube for treating persistent Eustachian tube dysfunction in adult patients using a transnasal approach.

In August 2021, the NuVent Eustachian Tube Dilation Balloon (Medtronic Xomed, Inc.) was cleared for marketing through the 501(k) process to treat persistent ETD in patients 18 years and older (K210841).

XprESS ENT Dilation System (Entellus Medical, Inc., Plymouth, MN) was approved by the FDA 510(k) process as a Class II device on April 4, 2017. This system is an expansion of the XprESS Multi-Sinus Dilation System "to dilate the cartilaginous portion of the Eustachian tube for treating persistent Eustachian tube dysfunction in patients 18 years and older using a transnasal approach" (FDA, 2017).

ETBD Literature Review:

Overall, the evidence in the published peer-reviewed literature supports the safety and efficacy of Eustachian tube dilation. Randomized controlled trials have compared ETBD to medical management alone (i.e., nasal topical steroids, auto inflation) and/or tympanoplasty alone for the treatment of obstructive ETD. Reported outcomes have shown that ETBD is noninferior to medical management and tympanoplasty with few to no reported complications (Kjær et al., 2022; Si, et al., 2019; Poe, et al., 2018; Meyer, et al., 2018; Liang, et al., 2016). Studies have primarily been in the form of case series and retrospective reviews with small, heterogeneous patient populations (Huisman, et al., 2018; Luukkhainen, et al., 2018; Schröder, et al., 2015; Silvola, et al., 2014; McCoul and Anand, 2012). Follow-up times vary but are typically 12 months or more.

Froehlich et al. (2020) conducted a systematic review and meta-analysis to examine the efficacy of Eustachian tube balloon dilation for Eustachian tube dysfunction. Twelve studies (n=448; 545 ears) including three randomized control trials, five prospective studies, and four case series met inclusion criteria. The inclusion criteria were adults diagnosed with ETD and one of the following outcome measures: ETDQ7 scores, tympanometry, otoscopy findings, and ability to perform Valsalva maneuver. From baseline to six weeks, ETDQ7 scores decreased by 2.13, 53.0% had improvement in tympanograms, and normal otoscopy exams increased by 30%. Baseline to long-term results (3-12 months) included 50.5% improved tympanograms, normal otoscopy exams increased by 55.4% and 67.8% increase in patients able to perform Valsalva maneuver. Author noted limitations included: possible theoretical publication bias due to only positive outcomes published in the individual studies; variations in surgical techniques including three different balloon dilation devices with different dilated diameters; some studies include patient populations with previous tympanostomy tubes or perforation at the time of balloon dilation.

Nibhanupudy et al. (2024) assessed topical intranasal corticosteroid efficacy in Eustachian tube dysfunction, and analyzed it's effect through tympanometric normalization. PubMed, EMBASE, Web of Science and Cochrane Library databases were searched. All RCTs assessing intranasal corticosteroids in adult or pediatric Eustachian tube dysfunction patients were included. Primary outcomes included changes in middle-ear fluid and negative middle-ear pressure severity (assessed through tympanometry and/or otoscopy), as well as Eustachian tube dysfunction symptomatology. Additional outcomes of interest included pure tone audiometry, adverse events, ability to delay procedural treatment, cost-effectiveness, quality of life (QoL) and nasopharyngoscopy, although analysis of these outcomes was not a requirement for study inclusion. Studies that were non-RCTs, non-English, still unpublished, or that focused on the incorrect patient population (e.g., patulous Eustachian tube dysfunction, acute otitis media, rhinosinusitis) or incorrect intervention (e.g., orally administered corticosteroids) were excluded. A

meta-analysis of proportions was used to evaluate tympanogram normalization. Of 330 results, eight randomized, controlled trials met inclusion criteria and underwent qualitative data synthesis and risk-of-bias analysis. Controls included placebo and/or no treatment in the selected studies. Meta-analysis of tympanometry data from four eligible trials ($n = 512$ ears) revealed no significant difference in tympanometric normalization between intranasal corticosteroids and control. The authors conclude that study results did not provide supportive evidence for the use of intranasal corticosteroids in Eustachian tube dysfunction. Neither intranasal corticosteroids nor control interventions were favored to a statistically significant degree when pooling tympanometric normalization rates from Eustachian tube dysfunction. Limitations included volume of data, heterogeneity, and mediocre study designs. These limitations emphasize the need for larger, higher quality, RCTs.

Wang et al. (2018) conducted a meta-analysis to examine balloon dilatation and laser tuboplasty for treatment of Eustachian tube dysfunction. Primary outcome measures for included studies were improvement of Eustachian tube score (ETS) and tympanometry and Valsalva maneuver results. Included were the results of two retrospective and eleven prospective studies which included both balloon tuboplasty and laser tuboplasty ($n=13$ studies; $n=1063$ patients; $n=942$ balloon tuboplasty; $n=121$ laser tuboplasty). Author concludes that balloon tuboplasty showed a statistically significant improvement of ETS overall ($p=0.009$). When compared with laser tuboplasty, balloon tuboplasty also showed a statistically significant improvement in tympanometry ($p=0.001$). Valsalva maneuver rate did not show a statistically significant difference between the procedures ($p=0.472$). Author noted limitations included heterogeneous outcome protocol between studies, sensitivity analysis indicated ETS results could have been overly influenced by two studies and no balloon tuboplasty studies reported ETS data which prevented comparison of two procedures.

Huisman et al. (2018) conducted a systematic review to evaluate effects of balloon dilation of the Eustachian tube in adult patients with Eustachian tube dysfunction. Inclusion criteria were balloon dilation of Eustachian tube (BDET) in adults with tube dysfunction. Eleven retrospective reviews and four case series ($n=1155$) met inclusion criteria. Outcome parameters included: relief of symptoms, otoscopy, Valsalva maneuver or Toynbee test, audiometry, tympanometry, Eustachian tube dysfunction classification, and Eustachian tube score. Patient populations were less than 70 with the exception of two studies ($n=271$; 622). Follow-ups primarily ranged from one week to 15 months. Several studies used BDET as an adjunct to other sinonasal and/or otologic procedures. All studies reported short-term improvement of original symptoms, and some showed further improvement over time. Meta-analysis was conducted in four subgroups: Valsalva maneuver, otoscopy, tympanometry, and Eustachian tube score. The Valsalva analysis ($n=5$ studies; 153 procedures) showed a significant decline of inability to perform the Valsalva maneuver after BDET ($p=0.0002$). A significant difference was seen in a decline in the inability to dilute the Eustachian tubes ($p=0.0002$) ($n=9$ studies; 255 procedures) and in the mean improvement in the ET score ($p<0.00001$). Six studies ($n=166$ procedures) showed a decline of otoscopic abnormal tympanic membranes after BDET, but the difference was not significant ($p=0.26$). Relatively mild and self-limiting complications were described in 36 patients. Most common events were a diffuse crush injury or local bleeding of the mucosa at the site of the Eustachian tube. The limitations of the study include the retrospective study design, small heterogenic patient populations, short-term follow-ups, heterogeneity of outcome measures, and high risk of bias.

A systematic review was conducted by Luukkainen et al. (2018) to identify studies reporting 12 months follow-up post BET. Five studies met the inclusion criterion (two prospective studies and three retrospective reviews). In the five individual studies, inclusion criteria varied and no two studies used the same outcome measures. No single outcome measure was used in all of the studies. Following BET, Valsalva maneuver improved in 80%–98% of patients, overall subjective symptoms improved in 73%–98%, and otoscopic findings improved in 90% of the patients.

Tympanometry and tubomanometry improved less, in 24%–54% and 28%–43% patients, respectively. Due to the limited number of studies, five additional studies with a 6–11 months follow-up were included and reported similar outcomes.

Poe et al. (2018) conducted a 2:1 ratio, randomized controlled trial (n=323 patients; 462 ears) to assess the safety and efficacy of balloon dilation of the Eustachian (BDET) using a custom-designed ET balloon catheter (ETBC) (Acclarent, Inc., Irvine, CA) in conjunction with medical management (MM) compared to MM alone in adult patients with drug-refractory Eustachian tube dilatory dysfunction (ETDD). Inclusion criteria were: 1) age \geq 22 years; 2) persistent ETDD (defined by patient-reported symptoms and at least one of the protocol defined confirmatory indicators for 12 weeks or more prior to enrollment); 3) a positive diagnosis of persistent ETDD was confirmed with both abnormal tympanometry and symptomatic dysfunction per Eustachian Tube Dysfunction Questionnaire-7 Symptom (ETDQ-7) mean item score 2.1 after failed MM; 4) transnasal endoscopy of the ET was performed and the degree of mucosal inflammation scored with a validated scale, 5) absence of internal carotid artery (ICA) dehiscence on both sides per computed tomography (CT) scan, and 6) failed MM (i.e., four weeks intranasal steroid spray or minimum of one completed course of an oral steroid within 90 days prior to study enrollment). The primary outcome measure was normalization of tympanometry at the six-week follow-up. Secondary outcome was improvement in ETDQ-7, tympanograms and mucosal inflammation. Follow-ups occurred at 2, 6, 12, and 24 weeks. At six weeks follow-up, failed controlled group patients had the option of crossing over to BDET. A statistically significant improvement in tympanogram normalization at the 6-week follow-up was reported in 51.8% (72/139) of the study group compared to 13.9% (10/72) of control group ($p < 0.0001$). At 24 weeks, tympanogram normalization was seen in 62.2% of BDET patients. Normalization of the ETDQ-7 scores at six weeks was observed in 56.2% (77/137) of the study group versus 8.5% (6/71) of controls ($p < 0.001$). However, this difference was not maintained at the 12- and 24-week follow-ups. Significantly more normal levels of mucosal inflammation were seen in the study groups versus the control group at the six-week follow-up ($p < 0.001$). The percentage of patients that could perform a positive modified Valsalva maneuver at 6-weeks was significantly higher in the study group ($p < 0.001$). Limitations of the study include: the short-term follow-up (6 weeks for the two randomized groups); 59 control group patients (82%) crossed over to BDET at the six-week follow-up period; and randomization was 2:1. According to the authors this is the first RCT investigating the safety and efficacy of BDET for ETDD compared to MM and they noted that MM has not been successful in treating ETDD. Anand et al. (2019) completed a follow up of this study focusing on twelve month outcomes of the Poe study. This was a prospective cohort from the previous multicenter randomized controlled trial. This study extends the follow up to fifty two weeks measuring ETDQ-7. The enrolled subjects (n=323) were randomized to BDET (n=149) and medical management (n=80) treatment groups. Primary endpoints and adverse events were described in original study. Results noted the subjects randomized to BDET and medical management remained comparable to those reported at six versus fifty two week follow-up: 73 of 143 (51.0%) versus 71 of 128 (55.5%); ETDQ-7, 79 of 142 (55.6%) versus 71 of 124 (57.3%). The overall number of ears with normalized tympanograms also remained comparable, with 117 of 204 (57%) versus 119 of 187 (63.6%).

Meyer et al. (2018) conducted a randomized controlled trial (n=60) to compare the safety and efficacy of Eustachian tube balloon dilation (n=31) versus continued medical therapy (n=29) (control) for treating persistent Eustachian tube dysfunction (ETD). Patients were included in the study if they were age \geq 18 years, had a diagnosis of ETD for 12 months or longer with \geq 3 ETD symptoms (ear pain, ear pressure, tinnitus, cracking or popping in ears, muffled hearing, feeling that ears were clogged) and had failed medical therapy. Failed medical therapy was defined as a minimum of either four weeks of daily intranasal steroid spray or one completed course of an oral steroid within 12 months before study enrollment. Patients were required to have an overall Eustachian Tube Dysfunction Questionnaire (ETDQ-7) score of \geq 3 (moderate to severe

symptoms). The primary outcome measures were the comparison between randomization arms for the mean change in overall ETDQ-7 scores from baseline to six weeks and complications related to the device or procedure. Secondary outcomes included technical success, procedural details, and differences between treatment arms for changes from baseline in tympanic membrane position, Valsalva maneuver, and tympanogram type. All planned in-office procedures were completed in the office with dilation durations of 2 minutes per Eustachian tube and were performed under topical and local anesthetics. At the six-week follow-up the ETDQ-7 score was significantly more improved than the control group ($p < 0.0001$). All dilation attempts were successful (91/91). For the patient with retracted tympanic membrane position measured at baseline ($n = 15$), 66.7% of those undergoing ETD showed an improvement at six weeks ($p = 0.002$) compared to no control patients ($n = 12$). The comparison between the groups was significantly different in favor of the ETD group ($p < 0.001$). Among the ears with type B or C tympanograms at baseline ($n = 14$ ETD; $n = 10$ control) there was a statistically significant improvement in favor of the ETD groups ($p = 0.006$). There was no significant difference between the groups for those patients who had a negative Valsalva maneuver at baseline. At the six-week follow-up 23 patients crossed over to ETD and 49 patients completed the one-year follow-up. The mean overall ETDQ-7 score was significantly reduced from 4.6 at baseline to 2.1 ($p < 0.0001$) 6 weeks following ETD maintained through the 12-month follow-up ($p < 0.0001$). At 12 months, patients with normal tympanic membrane position, type A tympanograms, and ability to clear the ears with Valsalva maneuver was significantly improved compared to baseline. No complications were reported. During the study, two participants underwent additional ear surgeries for continuing or recurring symptoms. Five patients were lost to the six-week follow-up. Limitations of the study include the small patient population; short-term follow-up; inability to blind the patients to their treatment; secondary outcome data was not available on all patients; five patients were lost to the six-week follow-up; and 23 patients crossed over to ETD after six weeks. Cutler et al. (2019) completed a follow up of the Meyer study focusing on outcomes greater than 12-months (mean 29.4 months; range 18-42 months). This was a prospective cohort from the previous multicenter randomized controlled trial. Participants of the extension study had to have undergone balloon dilation and completed the 12-month follow-up from the original study. Forty-seven participants were enrolled and evaluated at six-month intervals with the ETDQ-7 and middle ear functional assessments. Results noted that 93.6% of the subjects reported a reduction of one or more of their overall ETDQ-7 score with a mean score of 4.5 at baseline to 2.0 at last follow-up; tympanic membrane position improved from 46.8% within normal limits at baseline to 85.1% at last follow-up; Valsalva maneuver improved from 28.3% to 73.9%; and type A tympanograms improved from 70% to 86.3% at the last follow-up.

Randrup and Ovesen (2015) conducted a systematic review and meta-analysis of the literature to review the evidence of Eustachian tuboplasty (BET) for the treatment of ETD. Studies that included patients eligible for balloon Eustachian tuboplasty with a clinical diagnosis of Eustachian tube dysfunction were included. Outcome measures included: change in symptoms, middle ear pathology, eardrum status, Eustachian tube function tests, hearing, adverse events, complications, and health-related quality of life. Eight case series and one retrospective review with 8–210 patients (total $n = 443$ patients; 642 tubes) met inclusion criteria. Follow-ups primarily ranged from 8–30 weeks. A significant reduction of patient symptoms in ETD questionnaire ($p < 0.001$), reduction in Sino-Nasal Outcome Test (SNOT)-22 score ($p = 0.001$), and increased quality of life ($p = 0.001$) were reported. Postoperative normalization of the tympanic membrane, reduced mucosal inflammation, increased number of positive Valsalva test and swallowing tests, and improvement in ET score were also reported. Adverse events included mucosal tear, bleeding from turbinectomy site, tinnitus, and epistaxis. Comparison of results across the studies could not be made due to the heterogeneity of the inclusion criteria. Diagnostics and outcome measures varied. No study reported pre- and post-surgery results of pure-tone or speech audiometry. According to the authors, the evidence of BET was poor and featured a high risk of bias. No firm

conclusions could be made to identify patients who would benefit from the procedure or to accurately predict BET outcomes.

Gluth et al. (2011) conducted a randomized placebo-controlled, double blind prospective clinical trial. Their objective was to determine the efficacy of intranasal aqueous triamcinolone acetonide in treating the tympanometric signs and symptoms of Eustachian tube dysfunction, such as otitis media with effusion and negative middle ear pressure. Adults (≥ 18 years) and children (6-17 years) presenting with otitis media with effusion (OME), negative middle ear pressure, or both were included ($N=91$). The two treatment arms consisted of aqueous triamcinolone or matching placebo administered once daily intranasally for six weeks. All subjects underwent tympanometry, otologic examination, and completion of a symptom questionnaire before and after treatment. The primary outcome was resolution of abnormal tympanometry and change in symptom scores (severity and frequency). Ninety-one patients presenting from September 1, 2005, through December 31, 2008, with OME or with negative middle ear pressure were enrolled and randomly assigned to treatment or placebo in a double-blind manner. No statistically significant difference in normalization of abnormal tympanometric signs was demonstrated with the active treatment arm compared with placebo on either a per-patient basis (19% vs 32%; $P = 0.18$) or a per-ear basis (22% vs 35%; $P = 0.15$). There was also no significant difference in the overall poststudy symptom score between the two treatment arms, after adjusting for the pre-study overall symptom score in an analysis of covariance model ($P = 0.27$). The authors concluded that these findings do not support the use of intranasal steroid sprays to treat the manifestations of Eustachian tube dysfunction.

Pediatric ETBD Literature Review:

Merrill et al., 2023, performed a literature review to assess current evidence for ETBD in pediatric patients. Studies relevant to ETBD in the pediatric population were identified by utilizing the PubMed MEDLINE database. The team reviewed one systematic review (Saniasiaya et al., 2022) and one systematic review with meta-analysis (Aboueisha et al., 2022) based on retrospective case series and a retrospective cohort study. These studies are reviewed in greater detail within this section of the coverage policy. The authors conclude that while ETBD appears safe and efficacious in children with refractory ETD, future prospective trials to confirm this conclusion are warranted.

Gurberg et al. (2023) reported the long-term safety and efficacy of this procedure in children with a two-center retrospective matched cohort study. Balloon dilation of the Eustachian tube (BDET) has not been evaluated extensively in children outside of retrospective case series. The purpose of this study was to report the long-term safety and efficacy of this procedure in children with matched controls. Inclusion criteria included age < 18 years, indication for tympanostomy tube placement, middle ear fluid greater than three months duration or tympanic membrane retraction with accompanying hearing loss and failure on medical therapy. Exclusion criteria included conditions with increased susceptibility for otitis media with effusion and recurrent ear infections such as trisomy 21 and other syndromes, craniofacial anomalies, cleft palate, chronic inflammatory diseases, chronic ear disease (other than OME or AOM), and immunodeficiency. Children (age 14 months to 14 years) having undergone tympanostomy tube (TT) placement and adenoidectomy with recurrence of symptoms underwent BDET at an academic affiliated multi-specialty practice ($n=20$, 33 ears). Comparison was made with children receiving TT at a tertiary medical center, matching for number of prior TT, prior adenoidectomy, age, and sex. Outcome measures were risk of failure and the need for additional surgery. Kaplan-Meier survival plots were used to compare risk of failure. Patients undergoing BDET had normal post-operative tympanograms in 80% of cases. Mean follow up was 6.7 years with two patients failing in the BDET group and eight in the TT insertion group. Dilated patients had a significantly lower risk of failure than those who underwent TT insertion ($p = 0.03$). The probability of being failure free at

six years was 88 % (95 % CI: 71, 95 %) in the BDET cohort and 53 % (95 % CI: 33, 70 %) in the TT insertion cohort. There were no complications. Although there were no significant adverse events, the authors noted the need for continued vigilance and careful technique to assure safety in this age group due to shorter ET with different angles compared to adults. This study was completed off-label with devices that were not approved, nor designed for pediatric BDET. The authors state, "Great care is necessary to ensure that the balloon does not inadvertently pass into the bony ET, which would bring it into proximity with the internal carotid artery." The authors concluded BDET appeared to be safe and possibly superior to TT placement in children with refractory Eustachian tube dysfunction. Limitations of the study included the retrospective design (with all its inherent biases), small sample size, inclusion of three patients who could not be matched exactly for age, inclusion of concomitant procedures in the treatment group (FESS), and the fact that the two cohorts studied were from different geographic regions (Fort Worth, TX and Boston, MA) in the United States.

A systematic review and meta-analysis was conducted by Aboueisha et al. (2022) to determine the efficacy and safety of BDET amongst the pediatric population. A search, which returned seven studies (N=408) meeting criteria, was conducted using PubMed, Embase, Web of Science, Cochrane, Clinicaltrials.gov and CINAHL. Inclusion criteria consisted of children < 18 years of age with an intervention of BDET either alone or in combination with a tympanostomy or myringoplasty. The patients possessed a mean age of 9.9 years old (95 % CI: 8.8 to 11.1) and had a mean follow-up of 19.2 months (95 % CI: 15 to 23). Outcomes of efficacy included audiometric findings and adverse events (AEs) were summarized for each study. Preoperatively Type B tympanogram was the most common presentation with an air bone gap (ABG) mean of 22.8 dB. Following BDET, the authors found Type B tympanograms had decreased [64.2% (95% CI: 53.3 to 73.8) to 16.1% (95% CI: 8.5 to 28.4)]. The pooled estimate of AEs after BDET was 5.1 % (95 % CI: 3.2 to 8.1), the majority being self-limited epistaxis with no major AEs reported. Three studies compared BDET to ventilation tube insertion and analysis of post-operative ABG showed a greater decrease in the BDET group (mean difference -6.4 dB; 95 % CI: -9.8 to -3.1; p = 0.002). The authors concluded that although there are no prospective RCTs, BDET ± tympanostomy tube placement may produce outcomes that are comparable to tympanostomy tube placement in the treatment of OME in the pediatric population. Limitations included a small number of studies for analysis, lack of RCTs (majority of those included were retrospective), limited number of comparative studies, different indications for the use of BDET, and use of multiple types of balloons. Future RCTs in the pediatric population are needed to better determine the best candidates for BDET.

Saniasiaya et al. (2022) performed a systematic review to determine the outcome of Eustachian tube balloon dilation (ETBD) in children as the procedure has recently shown promising results in recalcitrant Eustachian tube dysfunction in adults. A literature search from 1990 to 2020 of several databases over a 1-month period (January 2021) according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Handbook for Systematic Reviews for Interventions was completed. The primary outcome was defined as the success of the intervention determined by the resolution of symptoms; the secondary outcome was determined by the need for revision surgery and the presence of complications. Only seven articles were identified based on the selection criteria. The studies included consisted of six retrospective cohort case series and one cohort of matched controls. A total of 284 patients were included in this review, with a mean age of 7.8 years. A total of 463 balloon dilations were performed either bilaterally or unilaterally. The most common finding of ETD was middle ear effusion in five of the seven studies. Balloon dilation of Eustachian tube was second line treatment in six studies and first line treatment in one study. Improvement of symptoms was identified in all studies via various assessments performed. Revision surgery was performed in one study with no major complications reported. The authors concluded that balloon dilation of the Eustachian tube may be considered as an alternative procedure following failed standard

treatment in children. The authors noted the quality of evidence was inadequate to recommend widespread use of the technique until better quality studies have been completed. They emphasized the need for randomized controlled trials (RCTs) with a large sample size to determine the efficacy of this procedure in children.

Technology Assessment: Hayes (2017) conducted a Technology Brief on the Acclarent Eustachian Tube Balloon Dilation System for the treatment of chronic Eustachian tube dysfunction in adults. The review identified five studies (n=22-109 patients; n=35-171 ears) that evaluated Eustachian tube balloon dilation (ETBD) using the Aera ETBD System or other sinus balloon systems manufactured by Acclarent Inc. Overall, the studies were of “very-low-quality” and did not allow for definitive conclusions regarding the efficacy, effectiveness, or safety of the Acclarent systems. Study interventions were heterogeneous, with a majority of studies including concurrent sinonasal and/or otologic procedures which limited the conclusions that could be drawn regarding the effectiveness of ETBD for chronic ETD. Overall, Follow-ups were short-term (3 months to 4.2 years). Definitive patient selection criteria could not be determined.

Professional Societies/Organizations

American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS): The AAO-HNS (2019) developed a clinical consensus statement on balloon dilation of the Eustachian tube (ET). The target population included adults \geq age 18 years with obstructive Eustachian tube dysfunction (ETD) in one or both ears for greater than three months affecting quality of life or functional health status for whom balloon dilation of the Eustachian tube was being recommended. Patients with patulous ETD, extrinsic obstruction of the ET, or active primary inflammatory disorders were excluded. Eustachian tube balloon dilation was defined as “inserting a catheter with a balloon temporarily into the cartilaginous portion of the ET and then inflating the balloon to alleviate obstructive ETD.” Due to the knowledge gap regarding the role of balloon dilation of the Eustachian tube (BDET) in managing obstructive ETD and an increasing rate of utilization, but limited evidence to support a clinical practice guideline, the topic of BDET was selected for clinical consensus statement development. Based on a systematic review of the literature and expert consensus, the Society’s statements included the following:

- “A comprehensive history and physical exam, including otoscopy, are essential parts of the diagnostic evaluation of a candidate for BDET”
- Nasal endoscopy is an essential part of the diagnostic evaluation prior to BDET.
- BDET is contraindicated for patients diagnosed as having a patulous ETD.
- Nasal endoscopy in patients who are candidates for BDET is necessary for assessing the ET lumen and assessing the feasibility of transnasal access to the nasopharynx.
- A diagnosis of patulous ETD is suggested by symptoms of autophony of voice, audible respirations, pulsatile tinnitus, and/or aural fullness.
- The benefit of repeat BDET after a prior ineffective BDET has not been determined.
- Symptoms of obstructive ETD can include aural fullness, aural pressure, hearing loss, and otalgia.
- Tympanometry is an essential part of the diagnostic evaluation prior to BDET.
- Establishing a diagnosis of obstructive ETD requires ruling out other causes of aural fullness such as patulous ETD, temporomandibular joint disorders, extrinsic obstruction of the ET, superior semicircular canal dehiscence, and endolymphatic hydrops.
- Patient-reported symptom scores alone are insufficient to establish a diagnosis of obstructive ETD.
- Nasal endoscopy is necessary to rule out extrinsic causes of ETD.
- Comprehensive audiometry is an essential part of the diagnostic evaluation prior to BDET.
- BDET is appropriate in patients with obstructive ETD who have failed medical therapy for identified treatable causes.

- Common causes of obstructive ETD that benefit from identification and management are allergic rhinitis, rhinosinusitis, and laryngopharyngeal reflux.
- Medical management of known pathology that could affect nasal or ET function is appropriate to perform prior to BDET.
- Patients with a history of recurrent barochallenge, defined as uncomfortable pressure in the ear upon exposure to ambient pressure changes that cannot be easily relieved, may improve following BDET.
- There is no scientifically proven or standard medical therapy for ETD.
- Pneumatic otoscopy can identify negative pressure in the middle ear space and can differentiate between adhesive and nonadhesive retractions of the tympanic membrane.
- Patients undergoing BDET concurrent with sinus ostial dilation should meet the same diagnostic criteria for BDET as those undergoing BDET alone.
- Potential risks of BDET that are relevant to patient counseling include bleeding, scarring, infection, development of patulous ETD, and/or the need for additional procedures.
- Myringotomy with or without tympanostomy tube placement is not a mandatory prerequisite to BDET.
- A dehiscence carotid artery identified on imaging is a contraindication to use of a device without a depth marker that demarcates insertion into the cartilaginous Eustachian tube.
- Patients with a middle ear effusion at the time of BDET may benefit from concurrent myringotomy with or without tympanostomy tube placement.
- BDET is an alternative to tympanostomy tube placement for obstructive ETD.
- Failure to relieve symptoms despite a functioning myringotomy or tympanostomy tube suggests a diagnosis other than obstructive ETD.
- Patient-reported symptom scores are useful in assessing baseline ETD symptoms and treatment outcomes.
- The ability to perform a modified Valsalva maneuver is appropriate for assessing outcome after BDET.
- Change in patient-reported symptom scores is appropriate for assessing outcome following BDET."

Medicare Coverage Determinations

	Contractor	Determination Name/Number	Revision Effective Date
NCD		No National Coverage Determination found	
LCD		No Local Coverage Determination found	

Note: Please review the current Medicare Policy for the most up-to-date information.
(NCD = National Coverage Determination; LCD = Local Coverage Determination)

Coding Information

Notes:

1. This list of codes may not be all-inclusive since the American Medical Association (AMA) and Centers for Medicare & Medicaid Services (CMS) code updates may occur more frequently than policy updates.
2. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Balloon Sinus Ostial Dilation

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT®* Codes	Description
31295	Nasal/sinus endoscopy, surgical, with dilation (eg, balloon dilation); maxillary sinus ostium, transnasal or via canine fossa
31296	Nasal/sinus endoscopy, surgical, with dilation (eg, balloon dilation); frontal sinus ostium
31297	Nasal/sinus endoscopy, surgical, with dilation (eg, balloon dilation); sphenoid sinus ostium
31298	Nasal/sinus endoscopy, surgical, with dilation (eg, balloon dilation); frontal and sphenoid sinus ostia

Eustachian Tube Dilation

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT®* Codes	Description
69705	Nasopharyngoscopy, surgical, with dilation of eustachian tube (i.e., balloon dilation); unilateral
69706	Nasopharyngoscopy, surgical, with dilation of eustachian tube (i.e., balloon dilation); bilateral

***Current Procedural Terminology (CPT®) ©2024 American Medical Association: Chicago, IL.**

References

1. Aboueisha MA, Attia AS, McCoul ED, Carter J. Efficacy and safety of balloon dilation of eustachian tube in children: Systematic review and meta-analysis. *Int J Pediatr Otorhinolaryngol*. 2022 Mar;154:111048. doi: 10.1016/j.ijporl.2022.111048. Epub 2022 Jan 21. PMID: 35085875.
2. Acclarent. Balloon Sinuplast Systems. 2021. Accessed April, 2 2025. Available at URL address: <https://www.acclarent.com/solutions/products/balloon-sinuplasty-system>
3. Achar P, Duvvi S, Kumar BN. Endoscopic dilatation sinus surgery (FEDS) versus functional endoscopic sinus surgery (FESS) for treatment of chronic rhinosinusitis: a pilot study. *Acta Otorhinolaryngol Ital*. 2012 Oct;32(5):314-9.
4. Ahmed J, Pal S, Hopkins C, Jayaraj S. Functional endoscopic balloon dilation of sinus ostia for chronic rhinosinusitis. *Cochrane Database Syst Rev*. 2011 Jul 6;(7):CD008515.
5. Albritton FD 4th, Casiano RR, Sillers MJ. Feasibility of in-office endoscopic sinus surgery with balloon sinus dilation. *Am J Rhinol Allergy*. 2012 May-Jun;26(3):243-8.
6. Anand, V., Poe, D., Dean, M., Roberts, W., Stolovitzky, P., Hoffmann, K., Nachlas, N., Light, J., Widick, M., Sugrue, J., Elliott, C. L., Rosenberg, S., Guillory, P., Brown, N., Syms, C., Hilton, C., McElveen, J., Singh, A., Weiss, R., Arriaga, M., ... Leopold, J. (2019). Balloon Dilation of the Eustachian Tube: 12-Month Follow-up of the Randomized Controlled Trial

Treatment Group. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 160(4), 687-694.

7. American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). Clinical consensus statement: Balloon dilation of the sinuses. Feb 1, 2018. Accessed April, 2 2025. Available at URL address: <https://www.entnet.org/quality-practice/quality-products/expert-consensus-statements/>
8. American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). Clinical Practice Guideline (Update): Adult Sinusitis. Apr, 2015. Accessed April, 2 2025. Available at URL address: <http://www.entnet.org/content/clinical-practice-guidelines>
9. American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). Policy Statement. Dilation of sinuses, any method (e.g., balloon, etc.). Revised Apr 13, 2021. Accessed April, 2 2025. Available at: <https://www.entnet.org/resource/position-statement-dilation-of-sinuses-any-method-e-g-balloon-etc/>
10. American Rhinologic Society (ARS). Ostial balloon dilation position statement. Mar 14, 2017. Updated Jan 2023. Accessed April, 2 2025. Available at URL address: <https://www.american-rhinologic.org/position-statements>
11. Bikhazi N, Light J, Truitt T, Schwartz M, Cutler J; REMODEL Study Investigators. Standalone balloon dilation versus sinus surgery for chronic rhinosinusitis: a prospective, multicenter, randomized, controlled trial with 1-year follow-up. Am J Rhinol Allergy. 2014 Jul-Aug;28(4):323-9.
12. Brodner D, Nachlas N, Mock P, Truitt T, Armstrong M, Pasha R, Jung C, Atkins J. Safety and outcomes following hybrid balloon and balloon-only procedures using a multifunction, multisinus balloon dilation tool. Int Forum Allergy Rhinol. 2013 Aug;3(8):652-8.
13. Brook I. [ed] Brush JL. Chronic sinusitis workup. Medscape. Jul 1, 2019. Updated Jan 19, 2022. Accessed April, 2 2025. Available at URL address: <http://emedicine.medscape.com/article/232791-workup#showall>
14. Brown CL, Bolger WE. Safety and feasibility of balloon catheter dilation of paranasal sinus ostia: a preliminary investigation. Ann Otol Rhinol Laryngol. 2006 Apr;115(4):293-9.
15. Catalano PJ, Payne SC. Balloon dilation of the frontal recess in patients with chronic frontal sinusitis and advanced sinus disease: an initial report. Ann Otol Rhinol Laryngol. 2009 Feb;118(2):107-12.
16. Centers for Medicare and Medicaid Services (CMS). Local Coverage Determinations (LCDs) alphabetical index. Accessed April, 2 2025. Available at URL address: <https://www.cms.gov/medicare-coverage-database/reports/local-coverage-proposed-lcds-alphabetical-report.aspx?proposedStatus=A&sortBy=title>
17. Centers for Medicare and Medicaid Services (CMS). National Coverage Determinations (NCDs) alphabetical index. Accessed April, 2 2025. Available at URL address: <https://www.cms.gov/medicare-coverage-database/reports/national-coverage-ncd-report.aspx?chapter=all&sortBy=title>

18. Chandra RK, Kern RC, Cutler JL, Welch KC, Russell PT. REMODEL larger cohort with long-term outcomes and meta-analysis of standalone balloon dilation studies. *Laryngoscope*. 2016 Jan;126(1):44-50.
19. Costa ML Psaltis AJ, Nayak JV, Hwang PH. Medical therapy vs surgery for recurrent acute rhinosinusitis. *Int Forum Allergy Rhinol*. 2015 Aug;5(8):667-73.
20. Cutler J, Bikhazi N, Light J, Truitt T, Schwartz M; REMODEL Study Investigators. Standalone balloon dilation versus sinus surgery for chronic rhinosinusitis: a prospective, multicenter, randomized, controlled trial. *Am J Rhinol Allergy*. 2013 Sep-Oct;27(5):416-22.
21. Cutler JL, Meyer TA, Nguyen SA, O'Malley EM, Thackeray L, Slater PW. Long-term Outcomes of Balloon Dilation for Persistent Eustachian Tube Dysfunction. *Otol Neurotol*. 2019;40(10):1322-1325.
22. Dass K, Peters AT. Diagnosis and Management of Rhinosinusitis: Highlights from the 2015 Practice Parameter. *Curr Allergy Asthma Rep*. 2016 Apr;16(4):29.
23. Froehlich MH, Le PT, Nguyen SA, McRackan TR, Rizk HG, Meyer TA. Eustachian Tube Balloon Dilation: A Systematic Review and Meta-analysis of Treatment Outcomes. *Otolaryngol Head Neck Surg*. 2020;163(5):870-882.
24. Gluth, Michael B et al. "Management of eustachian tube dysfunction with nasal steroid spray: a prospective, randomized, placebo-controlled trial." *Archives of otolaryngology--head & neck surgery* vol. 137,5 (2011): 449-55. doi:10.1001/archoto.2011.56
25. Gould J, Alexander I, Tomkin E, Brodner D. In-office, multisinus balloon dilation: 1-Year outcomes from a prospective, multicenter, open label trial. *Am J Rhinol Allergy*. 2014 Mar-Apr;28(2):156-63.
26. Gurberg, Joshua et al. "Long-term efficacy of balloon dilation of the pediatric Eustachian tube: A six-year matched cohort study." *American journal of otolaryngology* vol. 45,3 (2024): 104208. doi:10.1016/j.amjoto.2023.104208
27. Hamilos DL, Holbrook EH. Chronic Rhinosinusitis: Management. In: UpToDate, Kunins L (Ed). Last updated Sep 13, 2021. Waltham, MA. Accessed April, 2 2025.
28. Hathorn IF, Pace-Asciak P, Habib AR, Sunkaraneni V, Javer AR. Randomized controlled trial: hybrid technique using balloon dilation of the frontal sinus drainage pathway. *Int Forum Allergy Rhinol*. 2015 Feb;5(2):167-73.
29. Hayes, Inc. Directory. Balloon sinuplasty for treatment of chronic rhinosinusitis. Hayes, Inc.; Sept 15, 2016.
30. Hayes, Inc. Health Technology Assessment. Eustachian Tube Balloon Dilation for the Treatment of Chronic Eustachian Tube Dysfunction in Adults. Hayes, Inc.; Feb 16, 2021.
31. Hayes, Inc. Technology Brief. Acclarent eustachian tube balloon dilation for the treatment of chronic eustachian tube dysfunction in adults. Hayes, Inc.; Jul 2017.
32. Hepworth EJ. Balloon Sinuplasty. [Ed} Meyers AD. Medscape. Feb 23, 2016. Updated Dec 9, 2020. Accessed April, 2 2025. Available at URL address: <http://emedicine.medscape.com/article/1574031-overview#showall>

33. Hopkins C, Browne JP, Slack R, Lund V, Brown P. The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict? *Otolaryngol Head Neck Surg.* 2007 Oct;137(4):555-61.
34. Howard A , Babu S, Hauptert M, Thottam PJ. Balloon Eustachian tuboplasty in pediatric patients: Is it safe? *Laryngoscope.* 2021;131(7):1657-1662.
35. Huang BY, Lloyd KM, DelGaudio JM, Jablonowski E, Hudgins PA. Failed endoscopic sinus surgery: spectrum of CT findings in the frontal recess. *Radiographics.* 2009 Jan-Feb;29(1):177-95.
36. Huisman JML, Verdam FJ, Stegeman I, de Ru JA. Treatment of Eustachian tube dysfunction with balloon dilation: A systematic review. *Laryngoscope.* 2018 Jan;128(1):237-247.
37. Karanfilov B, Silvers S, Pasha R, Sikand A, Shikani A, Sillers M; ORIOS2 Study Investigators. Office-based balloon sinus dilation: a prospective, multicenter study of 203 patients. *Int Forum Allergy Rhinol.* 2013 May;3(5):404-11.
38. Kjær Krogshede S, Kirchmann M, Peter Schjellerup Jørkov A, Glad H. Balloon Dilation of the Eustachian Tube: A Randomized Controlled Trial with 6 Months Follow-Up. *J Int Adv Otol.* 2022 Nov;18(6):501-506. doi: 10.5152/iao.2022.21198. PMID: 36349672; PMCID: PMC9682787.
39. Kuhn FA, Church CA, Goldberg AN, Levine HL, Sillers MJ, Vaughan WC, Weiss RL. Balloon catheter sinusotomy: one-year follow-up--outcomes and role in functional endoscopic sinus surgery. *Otolaryngol Head Neck Surg.* 2008 Sep;139(3 Suppl 3):S27-37.
40. Levine SB, Truitt T, Schwartz M, Atkins J. In-office stand-alone balloon dilation of maxillary sinus ostia and ethmoid infundibula in adults with chronic or recurrent acute rhinosinusitis: a prospective, multi-institutional study with-1-year follow-up. *Ann Otol Rhinol Laryngol.* 2013 Nov;122(11):665-71.
41. Liang M, Xiong H, Cai Y, et al. Effect of the combination of balloon Eustachian tuboplasty and tympanic paracentesis on intractable chronic otitis media with effusion. *Am J Otolaryngol.* 2016;37(5):442-446.
42. Luukkainen V, Kivekäs I, Silvola J, Jero J, Sinkkonen ST. Balloon Eustachian Tuboplasty: Systematic Review of Long-term Outcomes and Proposed Indications. *J Int Adv Otol.* 2018 Apr;14(1):112-126.
43. Marom T, Isaacson G, Palazzi D. Otitis media with effusion (serous otitis media) in children: Management. In: UpToDate. Last updated Nov 14, 2024. Literature review current through March 2025. Waltham, MA. Accessed April 8, 2025.
44. Marzetti A, Tedaldi M, Passali FM. The role of balloon sinuplasty in the treatment of sinus headache. *Otolaryngol Pol.* 2014 Jan-Feb;68(1):15-9.
45. McCoul ED, Anand VK. Eustachian tube balloon dilation surgery. *Int Forum Allergy Rhinol.* 2012 May-Jun;2(3):191-8.
46. Medtronic. NuVent EM Balloon Sinus Dilation System. 2018. Accessed April, 2 2025. Available at URL address: <http://www.medtronic.com/us-en/healthcare->

professionals/products/ear-nose-throat/balloon-sinus-dilation/nuvent-em-balloon-sinus-dilation-system.html

47. Merrill, Tyler et al. "Is there a role for Eustachian tube balloon dilation in pediatric patients with refractory Eustachian tube dysfunction?." *American journal of otolaryngology* vol. 44,4 (2023): 103896. doi:10.1016/j.amjoto.2023.103896
48. Meyer TA, O'Malley EM, Schlosser RJ, et al. A Randomized Controlled Trial of Balloon Dilation as a Treatment for Persistent Eustachian Tube Dysfunction With 1-Year Follow-Up. *Otol Neurotol*. 2018;39(7):894-902.
49. Nibhanupudy, Tara J et al. "Efficacy of intranasal corticosteroid sprays in relieving clinical signs of Eustachian tube dysfunction: a systematic review and meta-analysis of randomised, controlled trials." *The Journal of laryngology and otology* vol. 138,11 (2024): 1065-1072. doi:10.1017/S0022215124000756
50. Noorian V, Motaghi A. Assessment of the Diagnostic Accuracy of Limited CT Scan of Paranasal Sinuses in the Identification of Sinusitis. *Iran Red Crescent Med J*. 2012 Nov;14(11):709-12.
51. Norman G, Llewellyn A, Harden M, Coatesworth A, Kimberling D, Schilder A, McDaid C. Systematic review of the limited evidence base for treatments of Eustachian tube dysfunction: a health technology assessment. *Clin Otolaryngol*. 2014 Feb;39(1):6-21. doi: 10.1111/coa.12220.
52. Orlandi RR, Kingdom TT, Hwang PH. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis Executive Summary. *Int Forum Allergy Rhinol*. 2016 Feb;6 Suppl 1:S3-S21.
53. Parikh A, Anand U, Ugwu MC, Feridooni T, Massoud E, Agu RU. Drug-eluting nasal implants: formulation, characterization, clinical applications and challenges. *Pharmaceutics*. 2014 May 27;6(2):249-67.
54. Payne SC, Stolovitzky P, Mehendale N, Matheny K, Brown W, Rieder A, Liepert D, Tseng E, Gould A, Powell S, Van Himbergen D, Karanfilov B, Harfe D, England L, Melroy C. Medical therapy versus sinus surgery by using balloon sinus dilation technology: A prospective multicenter study. *Am J Rhinol Allergy*. 2016 Jul;30(4):279-86.
55. Plaza G, Eisenberg G, Montojo J, Onrubia T, Urbasos M, O'Connor C. Balloon dilation of the frontal recess: a randomized clinical trial. *Ann Otol Rhinol Laryngol*. 2011 Aug;120(8):511-8.
56. Poe D, Anand V, Dean M, Roberts WH, Stolovitzky JP, Hoffmann K, Nachlas NE, Light JP, Widick MH, Sugrue JP0, Elliott CL, Rosenberg SI, Guillory P, Brown N, Syms CA 3rd, Hilton CW, McElveen JT Jr, Singh A, Weiss RL Jr, Arriaga MA, Leopold JP. Balloon dilation of the eustachian tube for dilatory dysfunction: A randomized controlled trial. *Laryngoscope*. 2018 May;128(5):1200-1206.
57. Poe D, Hanna B. Eustachian tube dysfunction. In: UpToDate, Kunins L (Ed). Last updated Nov 15, 2024. Waltham, MA. Accessed April 7, 2025.

58. Rak KM, Newell JD 2nd, Yakes WF, Damiano MA, Luethke JM. Paranasal sinuses on MR images of the brain: significance of mucosal thickening. *AJR Am J Roentgenol*. 1991 Feb;156(2):381-4.
59. Ramadan HH, McLaughlin K, Josephson G, Rimell F, Bent J, Parikh SR. Balloon catheter sinuplasty in young children. *Am J Rhinol Allergy*. 2010 Jan-Feb;24(1):e54-6.
60. Ramanan RV. [ed] Naul LG. Sinusitis imaging. Medscape. Jan 3, 2016. Updated Mar 1, 2021. Accessed April, 2 2025. Available at URL address: <http://emedicine.medscape.com/article/384649-overview>
61. Randrup TS, Ovesen T. Balloon eustachian tuboplasty: a systematic review. *Otolaryngol Head Neck Surg*. 2015 Mar;152(3):383-92.
62. Rank, Matthew A et al. "The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis." *The Journal of allergy and clinical immunology* vol. 151,2 (2023): 386-398. doi:10.1016/j.jaci.2022.10.026
63. Rege IC, Sousa TO, Leles CR, Mendonça EF. Occurrence of maxillary sinus abnormalities detected by cone beam CT in asymptomatic patients. *BMC Oral Health*. 2012 Aug 10;12:30.
64. Rudmik, L, Soler, ZM, Orlandi, RR, et al. Early postoperative care following endoscopic sinus surgery: an evidence-based review with recommendations. *International forum of allergy & rhinology*. 2011 Nov-Dec;1(6):417-30. PMID: 22144050.
65. Saniasiaya J, Kulasegarah J, Narayanan P, et al. Outcome of eustachian tube balloon dilation in children: A systematic review. *Ann Otol Rhinol Laryngol*. 2022;131(7):797-804
66. Schmitt D, Akkari M, Mura T, Mondain M, Uziel A, Venail F. Medium-term assessment of Eustachian tube function after balloon dilation. *Eur Ann Otorhinolaryngol Head Neck Dis*. 2018 Apr;135(2):105-110.
67. Schröder S, Lehmann M, Ebmeyer J, Upile T, Sudhoff H. Balloon Eustachian tuboplasty: a retrospective cohort study. *Clin Otolaryngol*. 2015 Dec;40(6):629-38.
68. Si Y, Chen Y, Xu G, Chen X, He W, Zhang Z. Cartilage tympanoplasty combined with eustachian tube balloon dilatation in the treatment of adhesive otitis media. *Laryngoscope*. 2019;129(6):1462-1467.
69. Sikand A, Silvers SL, Pasha R, Shikani A, Karanfilov BI, Harfe DT, Sillers MJ; ORIOS 2 Study Investigators. Office-Based Balloon Sinus Dilation: 1-Year Follow-up of a Prospective, Multicenter Study. *Ann Otol Rhinol Laryngol*. 2015 Aug;124(8):630-7.
70. Silvola J, Kivekäs I, Poe DS. Balloon Dilation of the Cartilaginous Portion of the Eustachian Tube. *Otolaryngol Head Neck Surg*. 2014 Jul;151(1):125-30.
71. SinuSys Corporation. Vent-Os Sinus Dilation System. 2016. Accessed April, 2 2025. Available at URL address: <http://sinustreatmentinfo.com/about-vent-os/>

72. Siu J, Klingler L, Wang Y, Hung CT, Jeong SH, Smith S, et al. Oral antibiotics used in the treatment of chronic rhinosinusitis have limited penetration into the sinonasal mucosa: a randomized trial. *Xenobiotica*. 2020;50(12):1443–50.
73. Smith SS, Kim R, Douglas R. Is there a role for antibiotics in the treatment of chronic rhinosinusitis? *J Allergy Clin Immunol*. 2022 May;149(5):1504-1512. doi: 10.1016/j.jaci.2022.02.004. Epub 2022 Feb 22. PMID: 35217148; PMCID: PMC11185277.
74. Song, H. Y., Park, H. J., Kang, W. S., Kim, K. Y., Park, J. H., Yoon, S. H., & Jeon, J. Y. (2019). Fluoroscopic Balloon Dilation Using a Flexible Guide Wire to Treat Obstructive Eustachian Tube Dysfunction. *Journal of vascular and interventional radiology : JVIR*, 30(10), 1562–1566.
75. Stankiewicz J, Tami T, Truitt T, Atkins J, Liepert D, Winegar B. Transantral, endoscopically guided balloon dilatation of the ostiomeatal complex for chronic rhinosinusitis under local anesthesia. *Am J Rhinol Allergy*. 2009 May-Jun;23(3):321-7.
76. Tisch M, Maier H, Sudhoff H. Balloon dilation of the Eustachian tube: clinical experience in the management of 126 children. *Acta Otorhinolaryngol Ital*. 2017 Dec;37(6):509-512.
77. Toivonen J, Kawai K, Gurberg J, Poe D. Balloon dilation for obstructive Eustachian tube dysfunction in children. *Otol Neurotol*. 2021;42(4):566-572.
78. Tucci DL, McCoul ED, Rosenfeld RM, et al. Clinical Consensus Statement: Balloon Dilation of the Eustachian Tube. *Otolaryngol Head Neck Surg*. 2019;161(1):6-17.
79. U.S. Food and Drug Administration (FDA). 510(k) premarket notification database. Accessed April, 2 2025. Available at URL address: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>
80. U.S. Food and Drug Administration (FDA). Eustachian tube balloon dilation device. DEN150056. 2016. Accessed April, 2 2025. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/denovo.cfm?ID=DEN150056>
81. U.S. Food and Drug Administration (FDA). Eustachian tube balloon dilation device. K171761. 2018. Accessed April, 2 2025. Available at URL address: https://www.accessdata.fda.gov/cdrh_docs/pdf17/K171761.pdf
82. U.S. Food and Drug Administration (FDA). Eustachian tube balloon dilation device. K230742. 2023. Accessed April, 2 2025. Available at URL address: 510(k) Premarket Notification (fda.gov)
83. U.S. Food and Drug Administration (FDA). Eustachian tube balloon dilation device. K230065. 2023. Accessed April, 2 2025. Available at URL address: 510(k) Premarket Notification
84. U.S. Food and Drug Administration (FDA). XprESS ENT Dilation System. K163509. 2017. Accessed April, 2 2025. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/>
85. Vartanian AJ, Meyers AD [ed] CT scan of the paranasal sinuses. *Medscape*. Aug 8, 2018. Accessed April, 2 2025. Available at URL address: <http://emedicine.medscape.com/article/875244-overview#showall>

86. Walters, Z. A., Phillips, K. M., Previtera, M. J., Gray, S. T., & Sedaghat, A. R. (2023). Minimal Radiographic Mucosal Thickness or Opacification Criterion for Sinus-Specific Endoscopic Sinus Surgery for Chronic Rhinosinusitis. *Otolaryngology–Head and Neck Surgery*, 169(2), 221-226.
87. Wang, T. C., Lin, C. D., Shih, T. C., Chung, H. K., Wang, C. Y., Tsou, Y. A., Huang, C. H., & Tsai, M. H. (2018). Comparison of Balloon Dilation and Laser Eustachian Tuboplasty in Patients with Eustachian Tube Dysfunction: A Meta-analysis. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery*, 158(4), 617–626.
88. Weiss RL, Church CA, Kuhn FA, Levine HL, Sillers MJ, Vaughan WC. Long-term outcome analysis of balloon catheter sinusotomy: two-year follow-up. *Otolaryngol Head Neck Surg*. 2008 Sep;139(3 Suppl 3):S38-46.

Revision Details

Type of Revision	Summary of Changes	Date
Annual Review	Revised policy statements for sinuplasty regarding mucosal thickening and antibiotics.	5/15/2025
Annual Review	No changes to coverage.	4/15/2024

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.